CN113038965B - Cxcr3的可切割激活剂及其使用方法 - Google Patents

Cxcr3的可切割激活剂及其使用方法 Download PDF

Info

Publication number
CN113038965B
CN113038965B CN201980069480.8A CN201980069480A CN113038965B CN 113038965 B CN113038965 B CN 113038965B CN 201980069480 A CN201980069480 A CN 201980069480A CN 113038965 B CN113038965 B CN 113038965B
Authority
CN
China
Prior art keywords
peptide
amino acid
cxcl
lys
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980069480.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113038965A (zh
Inventor
A·H·威尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Priority to CN202510050400.1A priority Critical patent/CN120022352A/zh
Publication of CN113038965A publication Critical patent/CN113038965A/zh
Application granted granted Critical
Publication of CN113038965B publication Critical patent/CN113038965B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980069480.8A 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法 Active CN113038965B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510050400.1A CN120022352A (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748711P 2018-10-22 2018-10-22
US62/748,711 2018-10-22
PCT/US2019/056955 WO2020086400A1 (en) 2018-10-22 2019-10-18 Cleavable activators of cxcr3 and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510050400.1A Division CN120022352A (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法

Publications (2)

Publication Number Publication Date
CN113038965A CN113038965A (zh) 2021-06-25
CN113038965B true CN113038965B (zh) 2025-02-07

Family

ID=70330587

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980069480.8A Active CN113038965B (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法
CN202510050400.1A Pending CN120022352A (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510050400.1A Pending CN120022352A (zh) 2018-10-22 2019-10-18 Cxcr3的可切割激活剂及其使用方法

Country Status (12)

Country Link
US (2) US12110316B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870212A4 (cg-RX-API-DMAC7.html)
JP (3) JP7426121B2 (cg-RX-API-DMAC7.html)
KR (2) KR102984527B1 (cg-RX-API-DMAC7.html)
CN (2) CN113038965B (cg-RX-API-DMAC7.html)
AU (2) AU2019365654B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007414A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116325A1 (cg-RX-API-DMAC7.html)
IL (2) IL282431B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004496A (cg-RX-API-DMAC7.html)
SG (1) SG11202103497WA (cg-RX-API-DMAC7.html)
WO (1) WO2020086400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103497WA (en) * 2018-10-22 2021-05-28 Univ Pittsburgh Commonwealth Sys Higher Education Cleavable activators of cxcr3 and methods of use
GB202208950D0 (en) * 2022-06-17 2022-08-10 Ucl Business Ltd Treatment of the corneal endothelium
US20260201006A1 (en) * 2022-11-30 2026-07-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Coacervate formulations of cxcr-activating peptides for controlled release in ophthalmic and topical treatments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039316A1 (en) * 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
WO2018191438A1 (en) * 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20070116669A1 (en) 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
GB2377444A (en) 2001-04-09 2003-01-15 Smithkline Beecham Plc Chemokine-family polypeptide
CA2525647A1 (en) * 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
WO2013032853A1 (en) 2011-08-26 2013-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activators of cxcr3 for the treatment of angiopathies of the eye
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
WO2015021058A2 (en) * 2013-08-05 2015-02-12 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
EP3096777B1 (en) * 2014-01-21 2021-01-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Goblet cell replacement therapy
EA035259B1 (ru) * 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
EP3478321A4 (en) * 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
SG11202103497WA (en) 2018-10-22 2021-05-28 Univ Pittsburgh Commonwealth Sys Higher Education Cleavable activators of cxcr3 and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039316A1 (en) * 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
WO2018191438A1 (en) * 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A CXCR3-Activating Peptide Increases Tear Break Up Time and Corrects Corneal haze in a Rabbit Model of Environmental Dry Eye;Alan Wells等;J Pharm Pharmacol Res.;20240417;第8卷(第2期);第23-27页 *
生物标志物在特发性肺纤维化中的研究新进展;贺朴等;中国现代医药杂志;20240725;第26卷(第7期);第105-110页 *

Also Published As

Publication number Publication date
IL324815A (en) 2026-01-01
MX2021004496A (es) 2021-06-04
KR20210081372A (ko) 2021-07-01
AU2019365654B2 (en) 2024-11-14
CN120022352A (zh) 2025-05-23
JP2024009210A (ja) 2024-01-19
IL282431B1 (en) 2025-12-01
AU2019365654A1 (en) 2021-05-13
KR20260109974A (ko) 2026-07-13
IL282431A (en) 2021-06-30
JP7798368B2 (ja) 2026-01-14
US20210388048A1 (en) 2021-12-16
CA3116325A1 (en) 2020-04-30
US20250002549A1 (en) 2025-01-02
JP7426121B2 (ja) 2024-02-01
JP2022512770A (ja) 2022-02-07
EP3870212A1 (en) 2021-09-01
AU2019365654A8 (en) 2021-05-20
KR102984527B1 (ko) 2026-06-30
IL282431B2 (en) 2026-04-01
CN113038965A (zh) 2021-06-25
JP2025172140A (ja) 2025-11-20
WO2020086400A1 (en) 2020-04-30
AU2025200880A1 (en) 2025-03-06
US12110316B2 (en) 2024-10-08
SG11202103497WA (en) 2021-05-28
EP3870212A4 (en) 2022-11-16
BR112021007414A2 (pt) 2021-08-10
AU2025200880B2 (en) 2026-06-04

Similar Documents

Publication Publication Date Title
JP7798368B2 (ja) Cxcr3の切断可能な活性化因子および使用方法
JP7725540B2 (ja) 眼の感染症および疾患を処置するための組成物および方法
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US20100323970A1 (en) Sap variants and their use
KR101214364B1 (ko) 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
EP3096777A1 (en) Goblet cell replacement therapy
KR20120093540A (ko) Fk506 결합 단백질 융합 단백질을 함유하는 안과 질환 예방 및 치료용 점안제 조성물
BG107685A (bg) Хемокинови мутанти за лечение на мултиплена склероза
CN102827253B (zh) 一种抑制炎症反应的小分子多肽及其应用
HK40055610A (en) Cleavable activator of cxcr3 and use method thereof
HK40123732A (en) Cleavable activators of cxcr3 and methods of use
HK40055610B (en) Cleavable activator of cxcr3 and use method thereof
CN103897034B (zh) 一种预防和/或治疗炎症反应的小分子多肽及其应用
AU2007226130B2 (en) Use of caspases for the preparation of medicaments
CN104371003A (zh) 预防和治疗炎症的小分子多肽及其应用
WO2014202834A1 (en) Protamine in treatment of neuronal injuries
EP2507266A2 (en) TREATMENT OF IgE-MEDIATED DISEASE
CN110092816B (zh) 预防和治疗纤维化的小分子多肽及其应用
JP2019523234A (ja) 眼疾患の処置
KR20210129823A (ko) 세포 침투성 펩타이드와 fkbp12를 포함하는 융합 단백질 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40055610

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant